G-Pola-GemOx in Refractory/Relapsed Aggressive B-Cell Lymphoma

NCT07184788 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Aggressive B-Cell Lymphoma

Interventions

DRUG: Glofitamab, Polatuzumab Vedotin, Gemcitabine, and Oxaliplatin as Induction Therapy

Sponsor

Navy General Hospital, Beijing